Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
Tabla de Políticas Médicas
| ID | Título | Revisión | Descripción | Acceso |
|---|---|---|---|---|
| P1.001.006 | Margenza | Sep 2026 | Margetuximab-cmkb (margenza™) was approved by the u.s. food and drug administration (fda) in december... | Ver |
| P1.001.007 | Monjuvi | Sep 2026 | Monjuvi (tafasitamab-cxix) is a cd19-directed cytolytic antibody indicated, in combination with lenalidomide,... | Ver |
| P1.001.008 | Rybrevant | Sep 2026 | Amivantamab-vmjw (rybrevant), a bispecific epidermal growth factor receptor (egfr) and met receptordirected... | Ver |
| P1.001.009 | Elahere (mirvetuximab soravtansine-gynx) | Sep 2026 | Elahere (mirvetuximab soravtansine-gynx) is a folate receptor alpha (frα)-directed antibody–drug... | Ver |
| P1.001.010 | Ublituximab-xiiy (Briumvi) | Sep 2026 | Multiple sclerosis (ms) is a chronic disease affecting the central nervous system (cns). it is characterized... | Ver |
| P1.001.011 | Imjudo (tremelimumab-actl) injection | Sep 2026 | Imjudo is indicated for the treatment of unresectable hepatocellular carcinoma (uhcc) and metastatic... | Ver |
| P1.001.012 | Teclistamab (Tecvayli) | Sep 2026 | ... | Ver |
| P1.001.013 | Enjaymo | Sep 2026 | Sutimlimab-jome (enjaymo) is a monoclonal antibody that inhibits the classical complement pathway by binding... | Ver |
| P1.001.014 | Opdualag | Sep 2026 | Nivolumab is a monoclonal antibody that enhances the antitumor immune response by binding to the programmed... | Ver |
| P1.001.015 | Xenpozyme | Sep 2026 | ... | Ver |
| P1.001.016 | Fyarro | Sep 2026 | Fyarro™ (nab-sirolimus) is an mtor inhibitor formulated as sirolimus protein-bound particles... | Ver |
| P1.002.001 | Vedolizumab | Dec 2025 | Vedolizumab is a recombinant human igg1 monoclonal antibody produced in chinese hamster ovaries. it binds to... | Ver |
| P1.002.002 | Benralizumab | Apr 2026 | Benralizumab is an interleukin-5 antagonist monoclonal antibody (igg1 kappa) for the add-on maintenance... | Ver |
| P1.002.003 | Somatuline® Depot; Lanreotide | Apr 2026 | Somatuline® depot; lanreotide is used to treat people with acromegaly (condition in which the body... | Ver |
| P1.002.004 | Nucala® (mepolizumab) | Dec 2025 | Nucala (mepolizumab) is an interleukin-5 receptor antagonist indicated for add-on maintenance treatment of... | Ver |
| P1.002.005 | Ocrevus™ (ocrelizumab) | Apr 2026 | Ocrelizumab is a humanized monoclonal antibody that is directed against cd20-expressing b-cells. cd20 is a... | Ver |
| P1.002.006 | Simponi ARIA® (golimumab) | Dec 2025 | Golimumab is in a class of drugs called biologics. golimumab is a treatment for adults with moderate to... | Ver |
| P1.002.007 | Stelara® (ustekinumab) | Dec 2025 | Stelara is a human igg1κ monoclonal antibody that binds with high affinity and specificity to the p40... | Ver |
| P1.002.008 | Tysabri® (natalizumab) | Dec 2025 | Natalizumab (tysabri) is a humanized monoclonal antibody that binds to alpha-4 integrin expressed on the... | Ver |
| P1.002.009 | Xolair® (omalizumab) | Dec 2025 | Omalizumab is an anti-ige monoclonal antibody produced by recombinant dna technology using chinese hamster... | Ver |